+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Is the apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 counteracted by concomitant 5-HT2C receptor antagonist treatment?



Is the apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 counteracted by concomitant 5-HT2C receptor antagonist treatment?



Society for Neuroscience Abstracts 24(1-2): 1369




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032052756

Download citation: RISBibTeXText


Related references

The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. Journal of Neural Transmission 104(4-5): 561-564, 1997

Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology 62(7): 2288-2298, 2012

M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18(3): 197-209, 1998

Effects of the 5-HT2A receptor antagonist, MDL 100,907 and the 5-HT2C receptor antagonist, SB 206553, on lordosis responding of female rats. Society for Neuroscience Abstracts 24(1-2): 1924, 1998

M100907, a selective serotonin 5-HT2A receptor antagonist and putative antipsychotic, reverses prepulse inhibition deficits in isolation-reared rats. Society for Neuroscience Abstracts 24(1-2): 1740, 1998

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. Journal of Neural Transmission 106(2): 123-129, 1999

M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20(4): 311-321, 1999

M100907, a highly selective 5-HT2A receptor antagonist and a potential atypical antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice. Brain Research. 779(1-2): 309-313,. 1, 1998

(+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10-methylindolo[1,7-bc][2,6]- naphthyridine: A 5-Ht2C/2B Receptor Antagonist with Low 5-Ht2A Receptor Affinity. Journal of Medicinal Chemistry 38(1): 28-33, 1995

(+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo[1,7- bc][2,6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity. Journal of Medicinal Chemistry 38(1): 28-33, 1995

5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study. Brain Research Bulletin 87(1): 44-49, 2012

5-HT2c receptor antagonists, but not a 5-HT2A or 5-HT2B receptor antagonist, attenuate haloperidol-induced catalepsy in rat. British Journal of Pharmacology 125(PROC Suppl. ): 65P, 1998

Differential effects of the 5-HT2A receptor antagonist MDL100,907 and the 5-HT2C receptor antagonist SB242,084 on cocaine induced locomotor activity, cocaine self-administration and cocaine induced reinstatement of responding. Society for Neuroscience Abstracts 27(1): 1176, 2001

Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. International Journal of Neuropsychopharmacology 4(4): 399-408, 2001

The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30(12): 2205-2215, 2005